Abstracts tagged "Cholesterol"

Abstract Number: 1545 • 2015 ACR/ARHP Annual Meeting
Comparison of Statin Eligibility According to the Adult Treatment Panel III, ACC/AHA Blood Cholesterol Guideline and Presence of Carotid Plaque By Ultrasound in Hispanics with Rheumatoid Arthritis
Alberto Cardenas-de La Garza¹, Raymundo Vera-Pineda², Dionicio A. Galarza-Delgado¹, Jose Ramon Azpiri-Lopez³, Iris J. Colunga-Pedraza¹, Jesus Zacarias Villarreal-Pérez⁴, Griselda Serna-Peña⁵ and Mario Alberto Garza-Elizondo¹, ¹Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ²Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ³Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Endocrinology, Hospital Universitario, UANL., Monterrey, Mexico, ⁵Internal Medicine, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Atherosclerotic cardiovascular disease (ASCVD) is the number one cause of death in rheumatoid arthritis (RA) patients. RA itself is an independent risk factor for…
Abstract Number: 1553 • 2015 ACR/ARHP Annual Meeting
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis
Michelle J. Ormseth¹, S. Louis Bridges Jr.², Jeffrey R. Curtis³, Joseph F. Solus⁴, Patricia Yancey⁵, MacRae F. Linton⁶, Sean Davies⁶, L Jackson Roberts II⁷, Kasey C. Vickers⁶, Valentina Kon⁶, Sergio Fazio⁸, C Michael Stein⁶ and TETRAD Investigators, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Pharmacology, Vanderbilt University, Nashville, TN, ⁵Medicine, Vanderbilt University, Nashville, TN, ⁶Vanderbilt University, Nashville, TN, ⁷Pharmacology, Vanderbilt University, Nashville, TN, ⁸Oregon Health and Science University, Portland, OR
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased coronary heart disease risk. Some RA therapies may modify this risk, but underlying mechanisms are unclear. The…
Abstract Number: 1580 • 2015 ACR/ARHP Annual Meeting
Abnormal High Density Lipoproteins in Synovial Fluid from Patients with Rheumatoid Arthritis Compared to Patients with Non-Inflammatory Arthritis
Christina Charles-Schoeman¹, Yuen Yin Lee², Ani Shahbazian¹, David Meriwether³, Peter Kim² and Srinivasa T. Reddy⁴, ¹Medicine-Rheumatology, University of California Los Angeles, Los Angeles, CA, ²Medicine- Rheumatology, University of California Los Angeles, Los Angeles, CA, ³Medicine- Cardiology, University of California Los Angeles, Los Angeles, CA, ⁴Medicine-Cardiology, University of California Los Angeles, Los Angeles, CA
Background/Purpose: High levels of rheumatoid arthritis (RA) disease activity have been associated with abnormal function of circulating high density lipoproteins (HDL) and increased cardiovascular…
Abstract Number: 1399 • 2014 ACR/ARHP Annual Meeting
Proteinase K-like Serine Protease PCSK9 Influence on the Dyslipidemia and Endothelial Dysfunction Observed in Rheumatoid Arthritis Patients
Esmeralda Delgado-Frias¹, Ivan Ferraz-Amaro², Vanesa Hernandez-Hernandez³, A.M. de Vera-Gonzalez⁴, A.F. Gonzalez-Rivero⁵, Miguel A. González-Gay⁶ and Federico Diaz-Gonzalez⁷, ¹Rheumatology, Servicio de Reumatología.Hospital Universitario de Canarias, La Laguna. Tenerife., Spain, ²Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ³Rheumatology, Servicio de Reumatologia.Hospital Universitario de Canarias., La Laguna. Tenerife, Spain, ⁴Laboratorio Central, Servicio de Laboratorio Central.Hospital Universitario de Canarias., La Laguna. Spain, Spain, ⁵Laboratorio Central, Servicio de Laboratorio Central. Hospital Universitario de Canarias., La Laguna. Tenerife., Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁷Rheumatology, Servicio de Reumatologia.Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose Proteinase K-like serine protease PCSK9 binds the low-density lipoprotein (LDL) receptor at the surface of hepatocytes, thereby preventing its recycling and enhancing its degradation…
Abstract Number: 1163 • 2014 ACR/ARHP Annual Meeting
Predictors of Cholesterol and Lifestyle Discussions in Rheumatoid Arthritis Visits: Impact of Perceived RA Control and Comparison with Other Prevention Topics
Christie M. Bartels¹, Joanna Wong², Heather Johnson³, Katya Voelker⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Tufts University School of Medicine, Boston, MA, ³Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Experts recommend discussing modifiable cardiovascular disease (CVD) risk factors in RA visits. We examined the predictors of discussions about cholesterol and or lifestyle (weight,…
Abstract Number: 843 • 2014 ACR/ARHP Annual Meeting
Exercise Is Associated with Protective Cardiovascular Risk Profile Including Increased HDL Particle Number in Patients with Rheumatoid Arthritis
Kevin Byram¹, Annette Oeser², MacRae F. Linton², Sergio Fazio², C Michael Stein² and Michelle Ormseth³, ¹Internal Medicine, Vanderbilt University, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased cardiovascular risk. In the general population, exercise improves several cardiovascular risk factors, including HDL cholesterol concentrations. Although…
Abstract Number: 488 • 2014 ACR/ARHP Annual Meeting
Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Joel M. Kremer¹, Mark C Genovese², Edward C. Keystone³, Peter C. Taylor⁴, Steven H. Zuckerman⁵, Douglas E. Schlichting⁵, Eric P. Nantz⁵, Scott D. Beattie⁵ and William L. Macias⁶, ¹Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ²Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³University of Toronto, Toronto, ON, Canada, ⁴NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Treatment with baricitinib (bari), an oral inhibitor of JAK1/JAK2, demonstrated improvements in signs and symptoms of RA through 52 wks in a Phase 2b…
Abstract Number: 487 • 2014 ACR/ARHP Annual Meeting
Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months
C. Charles-Schoeman¹, A. Dikranian², J. Taylor³, B. Wilkinson⁴, T. Jones⁵, K. Kwok⁶ and C. Nduaka⁴, ¹University of California, Los Angeles, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Anderson Arthritis and Rheumatology Center, Meridian, MS, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) increases in mean low-density lipoprotein cholesterol (LDL-C) and…
Abstract Number: 486 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Improves Arterial Stiffness Despite up-Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study
Kensuke Kume¹, Kanzo Amano², Susumu Yamada², Toshikatsu Kanazawa³, Hiroshi Komori⁴, Kazuhiko Hatta⁵, Kuniki Amano⁶ and Noriko Kuwaba⁷, ¹20-16 Higashi Kannon, Nishi Ward, hiroshima clinic, Hiroshima, Japan, ²Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴internal medicine, hiroshima clinic, hiroshima, Japan, ⁵Rheumatology, Hatta Clinic, Kure, Japan, ⁶Rheumatology, Sky Clinic, Hiroshima, Japan, ⁷Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascularprevention in RA. Tofacitinib (Tofa) could possibly…
Abstract Number: 229 • 2014 ACR/ARHP Annual Meeting
Correlates of Heel Bone Mass in Young Adults: The Role of Cholesterol over 20 Years from Childhood to Early Adulthood
Benny Samuel Eathakkattu Antony¹, Changhai Ding², Alison Venn³, Terry Dwyer⁴ and Graeme Jones², ¹Musculoskeletal, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Australia, ²Musculoskeletal Unit, Menzies Research Institute Tasmania, University of Tasmania, Hobart,7000, Australia, ³Epidemiology, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia, ⁴Director, Murdoch Children's Research Institute, Melbourne, Australia
Background/Purpose The association between lipids and bone mass in adult life is controversial and there is limited evidence in childhood. The aim of this study…
Abstract Number: 2950 • 2014 ACR/ARHP Annual Meeting
Synovial Macrophages Promote TGF-β Activation after Intra-Articular Injections of Oxidized LDL in Naïve Murine Knee Joints, Preventing Production of Pro-Inflammatory Factors S100A8/9, Chemokines and Aggrecanase-Induced Neo-Epitopes
Wouter de Munter, Peter M. van der Kraan, Wim B. van den Berg and Peter L. van Lent, Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: In previous studies we found that synovial macrophages regulate joint pathology during experimental osteoarthritis (OA). Recently, we found that high systemic levels of LDL…
Abstract Number: 2343 • 2013 ACR/ARHP Annual Meeting
Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis
Martin Soubrier¹, Thomas Frayssac², Bruno Pereira³, Marion Couderc Sr.⁴, Coline Daron², Jean Jacques Dubost⁵, Sandrine Malochet-Guinamand⁴, Anne Tournadre⁴ and Sylvain Mathieu⁴, ¹Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ²CHU CLERMONT-FERRAND, Clermont-ferrand, France, ³Clinical research department, Clermont-Ferrand, France, ⁴Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose: Increased incidence of cardiovascular diseases and sub-clinical atherosclerosis have been observed in rheumatoid arthritis (RA). Inflammation and traditional risk factors could be involved in…
Abstract Number: 1543 • 2013 ACR/ARHP Annual Meeting
Patients With Ankylosing Spondylitis Are Substantially Undertreated For Hypertension and Hypercholesterolemia
Sjoerd C. Heslinga^1,2,3, Inge A.M. van den Oever¹, Alper M. van Sijl^2,4, Irene E. Van der Horst-Bruinsma^4,5 and Michael. T. Nurmohamed^2,4, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with ankylosing spondylitis (AS) have a decreased life expectancy due to an increased cardiovascular (CV) risk. The general inflammatory process is held responsible…
Abstract Number: 1398 • 2013 ACR/ARHP Annual Meeting
Comparison Of Atherogenicity Of Plasma From Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Beenish Hafiz¹, Iryna Voloshyna², Michael J. Littlefield², Steven E. Carsons³, Elise Belilos¹, Kristina Belostocki¹, Lois A. Bonetti⁴, Gary C. Rosenblum¹ and Allison B. Reiss², ¹Rheumatology, Winthrop University Hospital, Mineola, NY, ²Medicine, Winthrop University Hospital, Mineola, NY, ³Div of Rheumatology, Winthrop University Hospital, Mineola, NY, ⁴Rheum & Immun, Winthrop University Hospital, Mineola, NY
Background/Purpose: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are immune mediated inflammatory disorders linked to increased risk of cardiovascular disease (CVD), mostly due to accelerated…
Abstract Number: 1407 • 2013 ACR/ARHP Annual Meeting
High Serum Cholesterol Predicts Rheumatoid Arthritis In Women
Carl Turesson¹, Ulf Bergström², Mitra Pikwer², Jan-Åke Nilsson² and Lennart Jacobsson², ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Patients with active rheumatoid arthritis (RA) tend to have low cholesterol levels due to effects of inflammation on lipid metabolism. However, several prospective studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].